Mount Sinai Researchers Uncover Unique Biological Markers in Patients With Mild Crohn’s Disease
Findings may help patients avoid overtreatment by guiding more personalized care
A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn’s disease, offering a potential pathway toward more personalized and less aggressive treatment strategies.
Published in Gastroenterology, the research is the first of its kind to use multi-omics data to study the biology of mild Crohn’s disease, a condition that affects nearly one in four patients but is often overlooked, as most Crohn’s disease research focuses on moderate-to-severe disease. Multi-omics is the combined study of different types of biological data (such as genes, proteins, and metabolites) to better understand how the body works and how diseases develop.
“These findings provide us with a new understanding of a large, overlooked group of patients,” said Ryan C. Ungaro, MD, MS, Associate Professor, Medicine (Gastroenterology), Icahn School of Medicine at Mount Sinai, and senior author of this study. “Our research shows that mild Crohn’s disease is not just a milder version of severe disease—it’s biologically distinct.”
Using data from two well-characterized patient cohorts—the Mount Sinai Crohn’s and Colitis Registry observational cohort and the Ocean State Crohn’s and Colitis Area Registry—first authors Arno Bourgonje, MD, PhD, and Susanne Ibing, PhD, postdoctoral fellows in gastroenterology at the Icahn School of Medicine, and the team discovered that patients with mild Crohn’s disease exhibited a reduced immune response and altered sphingolipid metabolism—a cellular process linked to immune regulation. These molecular markers form a kind of biological fingerprint associated with lower risk of disease progression. These markers also distinguish mild disease from more aggressive forms.
Shortly after diagnosis, many Crohn’s patients are prescribed advanced therapies that are aggressive, often costly, and lifelong treatments with potentially severe side effects (though rare). In a distinct subset of these patients, their symptoms never progress and they never need these advanced therapies. However, it is not yet well understood which patients will progress to more severe forms of the disease, and therefore will benefit from the advanced treatments. This study marks a major step toward navigating these nuances and providing precision medicine in inflammatory bowel disease (IBD), matching treatment intensity to the biology of the disease.
“We hope to develop tools that help physicians predict which patients are likely to have a mild, stable disease course,” said Jean-Frédéric Colombel, MD, Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai, and co-author on this paper. “That way, we can avoid unnecessary medications, reduce side effects, and lower costs for patients and the health care system. The findings in this paper could help change the outlook for patients with mild Crohn’s disease.” Dr. Colombel is also a Professor of Medicine (Gastroenterology).
The findings may support future use of biomarkers to identify patients who could safely delay or avoid biologic therapies. For patients, personalized care could mean fewer side effects, less time on medication, and lower treatment costs—especially for those with milder disease.
Looking ahead, researchers plan to validate these biomarkers in larger patient groups and develop clinically usable tools to help guide early treatment decisions.
Funding for the data used was provided by the National Institutes of Health and Janssen Pharmaceuticals.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.